Trial
NCT02730195
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
—
Condition
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Intervention
Pioglitazone
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-09